

# Ian Collins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/926400/publications.pdf>

Version: 2024-02-01

47  
papers

536  
citations

687363

13  
h-index

677142

22  
g-index

48  
all docs

48  
docs citations

48  
times ranked

1062  
citing authors

#	ARTICLE	IF	CITATIONS
1	Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study. <i>Supportive Care in Cancer</i> , 2022, 30, 8217-8229.	2.2	4
2	Measuring the quality of cancer care in the Barwon South Western region, Victoria, Australia. <i>International Journal for Quality in Health Care</i> , 2021, 33, .	1.8	3
3	Uptake of bone modifying agents in patients with HER2 + metastatic breast cancer with bone metastases – prospective data from a multi-site Australian registry. <i>Internal Medicine Journal</i> , 2021, , .	0.8	0
4	Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 87-95.	2.5	6
5	Real-world impact of anti-HER2 therapy-related cardiotoxicity in patients with advanced HER2-positive breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 356-362.	1.1	4
6	Teletrials: implementation of a new paradigm for clinical trials. <i>Medical Journal of Australia</i> , 2020, 213, 263.	1.7	19
7	Implementation of the Australasian Teletrial Model: Lessons from practice. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 3-14.	1.1	11
8	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz066.	2.9	8
9	Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial – Clinical outcomes and molecular determinants of response. <i>PLoS ONE</i> , 2019, 14, e0210891.	2.5	13
10	Consumer and clinician perspectives on personalising breast cancer prevention information. <i>Breast</i> , 2019, 43, 39-47.	2.2	22
11	Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3072-3072.	1.6	4
12	Learning from every patient: Real-world clinical outcomes of patients with metastatic triple-negative breast cancer treated in the community oncology setting.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12554-e12554.	1.6	0
13	Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms. <i>Medical Decision Making</i> , 2018, 38, 954-967.	2.4	13
14	The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing. <i>JMIR Formative Research</i> , 2018, 2, e24.	1.4	10
15	Influence of socioeconomic factors and distance to radiotherapy on breast-conserving surgery rates for early breast cancer in regional Australia; implications of change. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e224-e230.	1.1	10
16	Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?. <i>Australian Journal of Primary Health</i> , 2016, 22, 255.	0.9	16
17	A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 311-319.	4.9	17
18	Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. <i>Human Reproduction</i> , 2016, 31, 1126-1132.	0.9	84

#	ARTICLE	IF	CITATIONS
19	Anti-Müllerian Hormone Serum Concentrations of Women With Germline BRCA1 or BRCA2 Mutations. Obstetrical and Gynecological Survey, 2016, 71, 474-475.	0.4	2
20	iPrevent <sup>®</sup> : a tailored, web-based, decision support tool for breast cancer risk assessment and management. Breast Cancer Research and Treatment, 2016, 156, 171-182.	2.5	33
21	Tailored neoadjuvant epirubicin and cyclophosphamide (EC) and nanoparticle albumin-bound paclitaxel (nab-P) in breast cancer.. Journal of Clinical Oncology, 2016, 34, e12515-e12515.	1.6	0
22	Do women with <i>BRCA1</i> or <i>BRCA2</i> mutations have reduced ovarian reserve?. Journal of Clinical Oncology, 2015, 33, 1537-1537.	1.6	0
23	Women's preferences for selective estrogen reuptake modulators: An investigation using protection motivation theory. Patient Education and Counseling, 2014, 96, 106-112.	2.2	20
24	Rechallenge with imatinib in GIST: is more always RIGHT?. Lancet Oncology, The, 2014, 15, e2-e3.	10.7	5
25	Assessing and managing breast cancer risk: Clinicians' current practice and future needs. Breast, 2014, 23, 644-650.	2.2	44
26	Women's preferences for selective estrogen reuptake modulators: an investigation using the time trade-off technique. SpringerPlus, 2014, 3, 264.	1.2	3
27	Do <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuninghame Foundation Consortium for Research Into Familial Breast Cancer. Journal of Clinical Oncology, 2013, 31, 3920-3925.	1.6	42
28	Preventing breast and ovarian cancers in high-risk <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. Medical Journal of Australia, 2013, 199, 680-683.	1.7	39
29	Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want?. Journal of Clinical Oncology, 2013, 31, e20660-e20660.	1.6	2
30	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. Journal of Clinical Oncology, 2013, 31, 17-17.	1.6	1
31	Toxicity and relative dose intensity (RDI) of FOLFOX 6 chemotherapy in patients of differing body mass index treated for colorectal cancer. European Journal of Hospital Pharmacy, 2012, 19, 238.3-239.	1.1	1
32	Clinical Decision Aids in Colon Cancer: A Comparison of Two Predictive Nomograms. Clinical Colorectal Cancer, 2012, 11, 138-142.	2.3	10
33	Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland. Irish Journal of Medical Science, 2012, 181, 451-452.	1.5	1
34	Electronic clinical decision support systems attitudes and barriers to use in the oncology setting. Irish Journal of Medical Science, 2012, 181, 521-525.	1.5	11
35	Terminology and Details of the Diagnostic Process for Testis Cancer. Journal of Urology, 2011, 185, 876-880.	0.4	5
36	841 poster INDUCTION TPF IN LOCALLY ADVANCED HEAD AND NECK CANCER IN THE COMMUNITY SETTING: OUTCOMES AND TOXICITIES. Radiotherapy and Oncology, 2011, 99, S327.	0.6	0

#	ARTICLE	IF	CITATIONS
37	The tubal hypothesis of ovarian cancer: caution needed. <i>Lancet Oncology</i> , The, 2011, 12, 1089-1091.	10.7	24
38	Hodgkin lymphoma in the central nervous system. <i>Blood</i> , 2011, 118, 1721-1721.	1.4	1
39	Carboplatin Dosing in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1.	2.5	14
40	A Role for IGF-1R Targeted Therapies in Small-Cell Lung Cancer?. <i>Clinical Lung Cancer</i> , 2011, 12, 38-42.	2.6	8
41	Novel Approaches to Treatment of Leiomyosarcomas. <i>Current Oncology Reports</i> , 2011, 13, 316-322.	4.0	9
42	A Lung Cancer Responding to Hormonal Therapy. <i>Journal of Thoracic Oncology</i> , 2010, 5, 749-750.	1.1	4
43	Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor. <i>Acta Oncologica</i> , 2010, 49, 872-874.	1.8	8
44	A role for IGF-1R targeted therapy in SCLC?. <i>Lung Cancer</i> , 2010, 67, S12.	2.0	0
45	Waiting times for access, diagnosis and treatment in a cancer centre. <i>Irish Medical Journal</i> , 2009, 102, 279-82.	0.0	1
46	Bisphosphonate induced osteonecrosis of the jaws: Unravelling uncertainty in disease causality. <i>Acta Oncologica</i> , 2007, 46, 702-704.	1.8	4
47	Prostate cancer survival in South West Victoria. <i>Australian Journal of Rural Health</i> , 0, , .	1.5	0